Presentation is loading. Please wait.

Presentation is loading. Please wait.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Published byMarian Brož Modified over 5 years ago

Similar presentations

Presentation on theme: "Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3."— Presentation transcript:

1 Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. A, CTL induction against SCC3 cells from three spleens of anti-PD-1–treated mice. Levels of IFNγ produced by CTL cells stimulated with irradiated SCC-3 cells were measured using an ELISA Kit. Open column, control group; closed column, anti-PD-1–treated group. B, NK-cell cytotoxic activity of three spleens from anti-PD-1–treated mice. Cytotoxic activity was measured using the Nonradioactive Cytotoxicity Assay Kit. C, control group; T, anti-PD-1–treated group. Each column represents the mean value of the triplicate experiments. Tadashi Ashizawa et al. Clin Cancer Res 2017;23: ©2017 by American Association for Cancer Research

Download ppt "Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3."

Similar presentations

Glioma-derived soluble factor(s) enhance IL-10 signaling.

Glioma-derived soluble factor(s) enhance IL-10 signaling.
Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor
2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.

2aG4 directly induces monocytic MDSCs to differentiate into dendritic cells and macrophages by binding to phosphatidylserine on their cell surface. 2aG4.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
IFNα Induces MDSC Maturation and Loss of Suppressive Function

IFNα Induces MDSC Maturation and Loss of Suppressive Function
Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.

Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.
NK Cells Fighting Cancer

NK Cells Fighting Cancer
The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.
Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.
Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.

Interacting MDSCs and mast cells (MC) in human colon carcinoma and in the colon of AOM/DSS-induced tumor-bearing mice. Interacting MDSCs and mast cells.
Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

Similar presentations

Ads by Google